Halozyme(US:HALO) Prnewswire·2026-02-17 21:01Core Insights - Halozyme Therapeutics reported record total revenue of $1.4 billion for the full year 2025, representing a 38% year-over-year increase, driven by significant growth in royalty revenue and product sales [1][2][3] - The company reiterated its strong financial guidance for 2026, projecting total revenue between $1.710 billion and $1.810 billion, with year-over-year growth of 22% to 30% [1][3] - Halozyme expanded its drug delivery technology portfolio through acquisitions of Elektrofi and Surf Bio, enhancing its long-term royalty opportunities [1][2][3] Financial Performance - Full year 2025 royalty revenue reached a record $868 million, a 52% increase from 2024, primarily due to the success of ENHANZE-enabled products [1][2] - Fourth quarter 2025 total revenue was $451.8 million, up 52% from $298.0 million in the same quarter of 2024, with royalties contributing $258.0 million [2][5] - The company reported a net loss of $141.6 million in Q4 2025, compared to a net income of $137.0 million in Q4 2024, largely due to acquired in-process research and development expenses [2][5] 2026 Financial Guidance - Halozyme expects non-GAAP diluted earnings per share for 2026 to be between $7.75 and $8.25, reflecting growth of 87% to 99% over 2025 [1][3] - Adjusted EBITDA is projected to be between $1.125 billion and $1.205 billion, indicating growth of 71% to 83% over the previous year [1][3] - Royalty revenue for 2026 is anticipated to be between $1.130 billion and $1.170 billion, representing a growth of 30% to 35% compared to 2025 [3] Corporate Developments - In November 2025, Halozyme completed the acquisition of Elektrofi, enhancing its drug delivery technology portfolio [1][2] - The company also acquired Surf Bio in December 2025, further expanding its capabilities in drug delivery technologies [1][2] - Halozyme entered into multiple collaboration agreements with partners such as Takeda and Merus, broadening its market reach and product offerings [1][2]